(+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same
AssigneeKaken Pharmaceutical Co., Ltd.
InventorsNoriyuki Kamei, Daigo Kamimura, Yoshitake Sumikawa, Shota Tokuoka
Life of this patent
Estimating the term…
Abstract
Provided is (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof. Also provided is a drug containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.
Claims21
(+)-5-(3,4-Difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.
A method of producing (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, comprising optically resolving a racemate (±)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1 (2H)-yl)methyl]imidazolidine-2,4-dione by chromatography using a column for optical separation.
(+)-5-(3,4-Difluorophenyl)-5-[(3-methyl-2-oxopyridin-1 (2H)-yl)methyl]imidazolidine-2,4-dione obtainable by optically resolving a racemate (±)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione by chromatography using a column for optical separation.
A mixture of (+)- and (−)-isomers of 5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, wherein the (+)-isomer exists at 90% ee or more to the (−)-isomer.
Dependencies are inferred from the claim text.